Breast cancer-derived extracellular vesicles: Characterization and contribution to the metastatic phenotype

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Green, Toni M ^a   Alpaugh, Mary L ^b   Barsky, Sanford H ^a   Rappa, Germana ^a   Lorico, Aurelio ^a  

^a ROSEMAN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT; MICRORNA; PROTEIN; TUMOR MARKER; RNA; TRANSFER RNA; TUMOR PROTEIN;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL DIFFERENTIATION; DISEASE TRANSMISSION; EXOSOME; HUMAN; METASTASIS; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SCANNING ELECTRON MICROSCOPY; TARGET CELL; TUMOR MICROENVIRONMENT; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; MEMBRANE MICROPARTICLE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL-DERIVED MICROPARTICLES; EXOSOMES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; RNA, NEOPLASM; RNA, TRANSFER; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84947561584     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/634865     Document Type: Review

References (165)

1. C. E. Desantis, C. C. Lin, A. B. Mariotto et al., "Cancer treatment and survivorship statistics, 2014," CA Cancer Journal for Clinicians, vol. 64, no. 4, pp. 252-271, 2014.
2. G. Mustacchi, L. Biganzoli, P. Pronzato et al., "HER2-positive metastatic breast cancer: a changing scenario," Critical Reviews in Oncology/Hematology, vol. 95, no. 1, pp. 78-87, 2015.
3. A. Sonnenblick and M. Piccart, "Adjuvant systemic therapy in breast cancer: quo vadis?" Annals of Oncology, vol. 26, no. 8, pp. 1629-1634, 2015.
4. S. Tangutoori, P. Baldwin, and S. Sridhar, "PARP inhibitors: a new era of targeted therapy," Maturitas, vol. 81, no. 1, pp. 5-9, 2015.
5. R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2015," CA Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5-29, 2015.
6. D. P. Kodack, V. Askoxylakis, G. B. Ferraro, D. Fukumura, and R. K. Jain, "Emerging strategies for treating brain metastases from breast cancer," Cancer Cell, vol. 27, no. 2, pp. 163-175, 2015.
7. L. Gerratana, V. Fanotto, M. Bonotto et al., "Pattern of metastasis and outcome in patients with breast cancer," Clinical and Experimental Metastasis, vol. 32, pp. 125-133, 2015.
8. A. J. Redig and S. S. Mcallister, "Breast cancer as a systemic disease: a view of metastasis," Journal of Internal Medicine, vol. 274, no. 2, pp. 113-126, 2013.
9. T. H. Lee, E. D'Asti, N. Magnus, K. Al-Nedawi, B. Meehan, and J. Rak, "Microvesicles as mediators of intercellular communication in cancer-the emerging science of cellular 'debris'," Seminars in Immunopathology, vol. 33, no. 5, pp. 455-467, 2011.
10. E. van der Pol, A. N. Böing, P. Harrison, A. Sturk, and R. Nieuwland, "Classifcation, functions, and clinical relevance of extracellular vesicles," Pharmacological Reviews, vol. 64, no. 3, pp. 676-705, 2012.
11. F. Jansen, X. Yang, S. Proebsting et al., "MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease," Journal of the American Heart Association, vol. 3, no. 6, Article ID e001249, 2014.
12. F. Pucci and M. J. Pittet, "Molecular pathways: tumor-derived microvesicles and their interactions with immune cells in vivo," Clinical Cancer Research, vol. 19, no. 10, pp. 2598-2604, 2013.
13. G. Camussi, M. C. Deregibus, S. Bruno, V. Cantaluppi, and L. Biancone, "Exosomes/microvesicles as a mechanism of cell-to-cell communication," Kidney International, vol. 78, no. 9, pp. 838-848, 2010.
14. K. Denzer, M. J. Kleijmeer, H. F. G. Heijnen, W. Stoorvogel, and H. J. Geuze, "Exosome: from internal vesicle of the multivesicular body to intercellular signaling device," Journal of Cell Science, vol. 113, no. 19, pp. 3365-3374, 2000.
15. J. H. Hurley and G. Odorizzi, "Get on the exosome bus with ALIX," Nature Cell Biology, vol. 14, no. 7, pp. 654-655, 2012.
16. L. Urbanelli, A. Magini, S. Buratta et al., "Signaling pathways in exosomes biogenesis, secretion and fate," Genes, vol. 4, no. 2, pp. 152-170, 2013.
17. G. Raposo and W. Stoorvogel, "Extracellular vesicles: exosomes, microvesicles, and friends," The Journal of Cell Biology, vol. 200, no. 4, pp. 373-383, 2013.
18. H. F. G. Heijnen, A. E. Schiel, R. Fijnheer, H. J. Geuze, and J. J. Sixma, "Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and β-granules," Blood, vol. 94, no. 11, pp. 3791-3799, 1999.
19. V. Muralidharan-Chari, J. W. Clancy, A. Sedgwick, and C. D'Souza-Schorey, "Microvesicles: mediators of extracellular communication during cancer progression," Journal of Cell Science, vol. 123, no. 10, pp. 1603-1611, 2010.
20. A. E. Morelli, A. T. Larregina, W. J. Shufesky et al., "Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells," Blood, vol. 104, no. 10, pp. 3257-3266, 2004.
21. I. Del Conde, C. N. Shrimpton, P. Tiagarajan, and J. A. López, "Tissue-factor-bearing microvesicles arise from lipid rafs and fuse with activated platelets to initiate coagulation," Blood, vol. 106, no. 5, pp. 1604-1611, 2005.
22. R. B. Koumangoye, A. M. Sakwe, J. S. Goodwin, T. Patel, and J. Ochieng, "Detachment of breast tumor cells induces rapid secretion of exosomes which subsequently mediate cellular adhesion and spreading," PLoS ONE, vol. 6, no. 9, Article ID e24234, 2011.
23. A. Elmi, E. Watson, P. Sandu et al., "Campylobacter jejuni outer membrane vesicles play an important role in bacterial interactions with human intestinal epithelial cells," Infection and Immunity, vol. 80, no. 12, pp. 4089-4098, 2012.
24. I. Parolini, C. Federici, C. Raggi et al., "Microenvironmental pH is a key factor for exosome trafc in tumor cells," The Journal of Biological Chemistry, vol. 284, no. 49, pp. 34211-34222, 2009.
25. X. Loyer, A.-C. Vion, A. Tedgui, and C. M. Boulanger, "Microvesicles as cell-cell messengers in cardiovascular diseases," Circulation Research, vol. 114, no. 2, pp. 345-353, 2014.
26. F. F. Van Doormaal, A. Kleinjan, M. Di Nisio, H. R. Büller, and R. Nieuwland, "Cell-derived microvesicles and cancer," Netherlands Journal of Medicine, vol. 67, no. 7, pp. 266-273, 2009.
27. A. Vargas, S. Zhou, M. Éthier-Chiasson et al., "Syncytin proteins incorporated in placenta exosomes are important for cell uptake and show variation in abundance in serum exosomes from patients with preeclampsia," The FASEB Journal, vol. 28, no. 8, pp. 3703-3719, 2014.
28. C. Tery, S. Amigorena, G. Raposo, and A. Clayton, "Isolation and characterization of exosomes from cell culture supernatants and biological fuids," Current Protocols in Cell Biology, chapter 3: unit 3.22, 2006.
29. A. Al Faraj, F. Gazeau, C. Wilhelm et al., "Endothelial cell-derived microparticles loaded with iron oxide nanoparticles: feasibility of MR imaging monitoring in mice," Radiology, vol. 263, no. 1, pp. 169-178, 2012.
30. A. S. Haqqani, C. E. Delaney, T.-L. Tremblay, C. Sodja, J. K. Sandhu, and D. B. Stanimirovic, "Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells," Fluids and Barriers of the CNS, vol. 10, no. 1, article 4, 2013.
31. L. Comelli, S. Rocchiccioli, S. Smirni et al., "Characterization of secreted vesicles from vascular smooth muscle cells," Molecular BioSystems, vol. 10, no. 5, pp. 1146-1152, 2014.
32. Y. Wei, X. Lai, S. Yu et al., "Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells," Breast Cancer Research and Treatment, vol. 147, pp. 423-431, 2014.
33. A. Clayton and Z. Tabi, "Exosomes and the MICA-NKG2D system in cancer," Blood Cells, Molecules, and Diseases, vol. 34, no. 3, pp. 206-213, 2005.
34. R. Crescitelli, C. Lasser, T. G. Szabó et al., "Distinct RNA profles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes," Journal of Extracellular Vesicles, vol. 2, Article ID 20677, 2013.
35. E. Ĺazaro-Ibáñez, A. Sanz-Garcia, T. Visakorpi et al., "Difer-ent gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exo-somes," Prostate, vol. 74, no. 14, pp. 1379-1390, 2014.
36. S. Staubach, H. Razawi, and F.-G. Hanisch, "Proteomics of MUC1-containing lipid rafs from plasma membranes and exosomes of human breast carcinoma cells MCF-7," Proteomics, vol. 9, no. 10, pp. 2820-2835, 2009.
37. Y. Zheng, E. C. Campbell, J. Lucocq, A. Riches, and S. J. Powis, "Monitoring the Rab27 associated exosome pathway using nanoparticle tracking analysis," Experimental Cell Research, vol. 319, no. 12, pp. 1706-1713, 2013.
38. G. Rappa, J. Mercapide, F. Anzanello, R. M. Pope, and A. Lorico, "Biochemical and biological characterization of exosomes containing prominin-1/CD133," Molecular Cancer, vol. 12, article 62, 2013.
39. S.-I. Ohno, M. Takanashi, K. Sudo et al., "Systemically injected exosomes targeted to EGFR deliver antitumor microrna to breast cancer cells," Molecular Terapy, vol. 21, no. 1, pp. 185-191, 2013.
40. V. Ciravolo, V. Huber, G. C. Ghedini et al., "Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy," Journal of Cellular Physiology, vol. 227, no. 2, pp. 658-667, 2012.
41. O. Galindo-Hernandez, S. Villegas-Comonfort, F. Candanedo et al., "Elevated concentration of microvesicles isolated from peripheral blood in breast cancer patients," Archives of Medical Research, vol. 44, no. 3, pp. 208-214, 2013.
42. K. Menck, C. Scharf, A. Bleckmann et al., "Tumor-derived microvesicles mediate human breast cancer invasion through diferentially glycosylated EMMPRIN," Journal of Molecular Cell Biology, vol. 7, no. 2, pp. 143-153, 2015.
43. T. Wang, D. M. Gilkes, N. Takano et al., "Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis," Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 31, pp. E3234-E3242, 2014.
44. M. P. Bard, J. P. Hegmans, A. Hemmes et al., "Proteomic analysis of exosomes isolated from human malignant pleural efusions," American Journal of Respiratory Cell and Molecular Biology, vol. 31, no. 1, pp. 114-121, 2004.
45. H. W. King, M. Z. Michael, and J. M. Gleadle, "Hypoxic enhancement of exosome release by breast cancer cells," BMC Cancer, vol. 12, article 421, 2012.
46. G. Nangami, R. Koumangoye, J. S. Goodwin et al., "Fetuin-A associates with histones intracellularly and shuttles them to exosomes to promote focal adhesion assembly resulting in rapid adhesion and spreading in breast carcinoma cells," Experimental Cell Research, vol. 328, no. 2, pp. 388-400, 2014.
47. W.-X. Chen, X.-M. Liu, M.-M. Lv et al., "Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of micrornas," PLoS ONE, vol. 9, no. 4, Article ID e95240, 2014.
48. J. Palma, S. C. Yaddanapudi, L. Pigati et al., "MicroRNAs are exported from malignant cells in customized particles," Nucleic Acids Research, vol. 40, no. 18, pp. 9125-9138, 2012.
49. S. Dutta, C. Warshall, C. Bandyopadhyay, D. Dutta, and B. Chandran, "Interactions between exosomes from breast cancer cells and primary mammary epithelial cells leads to generation of reactive oxygen species which induce DNA damage response, stabilization of p53 and autophagy in epithelial cells," PLoS ONE, vol. 9, no. 5, Article ID e97580, 2014.
50. K. O'Brien, S. Rani, C. Corcoran et al., "Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells," European Journal of Cancer, vol. 49, no. 8, pp. 1845-1859, 2013.
51. J. N. Higginbotham, M. Demory Beckler, J. D. Gephart et al., "Amphiregulin exosomes increase cancer cell invasion," Current Biology, vol. 21, no. 9, pp. 779-786, 2011.
52. R. Singh, R. Pochampally, K. Watabe, Z. Lu, and Y. Mo, "Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer," Molecular Cancer, vol. 13, article 256, 2014.
53. D. Gheldof, J. Hardij, F. Cecchet, B. Chatelain, J. Dogńe, and F. Mullier, "Trombin generation assay and transmission electron microscopy: a useful combination to study tissue factor-bearing microvesicles," Journal of Extracellular Vesicles, vol. 2, 2013.
54. C. Ettelaie, M. E. Collier, A. Maraveyas, and R. Ettelaie, "Characterization of physical properties of tissue factor-containing microvesicles and a comparison of ultracentrifuge-based recovery procedures," Journal of Extracellular Vesicles, vol. 3, Article ID 23592, 2014.
55. M. Kesimer, M. Scull, B. Brighton et al., "Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense," The FASEB Journal, vol. 23, no. 6, pp. 1858-1868, 2009.
56. G. Palazzolo, N. N. Albanese, G. Di Cara, D. Gygax, M. L. Vittorelli, and I. Pucci-Minafra, "Proteomic analysis of exosome-like vesicles derived from breast cancer cells," Anticancer Research, vol. 32, no. 3, pp. 847-860, 2012.
57. S. Kruger, Z. Y. A. Elmageed, D. H. Hawke et al., "Molecular characterization of exosome-like vesicles from breast cancer cells," BMC Cancer, vol. 14, no. 1, article 44, 2014.
58. P. Jenjaroenpun, Y. Kremenska, V. M. Nair, M. Kremenskoy, B. Joseph, and I. V. Kurochkin, "Characterization of RNA in exosomes secreted by human breast cancer cell lines using next-generation sequencing," PeerJ, vol. 2013, no. 1, article e201, 2013.
59. J. Silva, V. Garcia, M. Rodriguez et al., "Analysis of exosome release and its prognostic value in human colorectal cancer," Genes, Chromosomes and Cancer, vol. 51, no. 4, pp. 409-418, 2012.
60. M. Logozzi, A. De Milito, L. Lugini et al., "High levels of exo-somes expressing CD63 and caveolin-1 in plasma of melanoma patients," PLoS ONE, vol. 4, no. 4, Article ID e5219, 2009.
61. D. D. Taylor and C. Gercel-Taylor, "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer," Gynecologic Oncology, vol. 110, no. 1, pp. 13-21, 2008.
62. M. J. Szczepanski, M. Szajnik, A. Welsh, T. L. Whiteside, and M. Boyiadzis, "Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-β1," Haematologica, vol. 96, no. 9, pp. 1302-1309, 2011.
63. + T lymphocytes," Journal of Immunology, vol. 183, no. 6, pp. 3720-3730, 2009.
64. S. A. Melo, H. Sugimoto, J. T. O'Connell et al., "Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis," Cancer Cell, vol. 26, no. 5, pp. 707-721, 2014.
65. A.-K. Rupp, C. Rupp, S. Keller et al., "Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage," Gynecologic Oncology, vol. 122, no. 2, pp. 437-446, 2011.
66. X. Fang, P. Zheng, J. Tang, and Y. Liu, "CD24: from A to Z," Cellular and Molecular Immunology, vol. 7, no. 2, pp. 100-103, 2010.
67. V. M. Golubovskaya, F. A. Kwen, and W. G. Cance, "Focal adhesion kinase and cancer," Histology and Histopathology, vol. 24, no. 4, pp. 503-510, 2009.
68. N. Normanno, A. De Luca, C. Bianco et al., "Epidermal growth factor receptor (EGFR) signaling in cancer," Gene, vol. 366, no. 1, pp. 2-16, 2006.
69. S. Fukuda and L. M. Pelus, "Survivin, a cancer target with an emerging role in normal adult tissues," Molecular Cancer Terapeutics, vol. 5, no. 5, pp. 1087-1098, 2006.
70. S. Khan, H. F. Bennit, D. Turay et al., "Early diagnostic value of survivin and its alternative splice variants in breast cancer," BMC Cancer, vol. 14, no. 1, article 176, 2014.
71. X. Yang, O. V. Kovalenko, W. Tang, C. Claas, C. S. Stipp, and M. E. Hemler, "Palmitoylation supports assembly and function of integrin-tetraspanin complexes," Journal of Cell Biology, vol. 167, no. 6, pp. 1231-1240, 2004.
72. E. Gustafson-Wagner and C. S. Stipp, "The CD9/CD81 tetraspanin complex and tetraspanin CD151 regulate alpha3beta1 integrin-dependent tumor cell behaviors by overlapping but distinct mechanisms," PLoS ONE, vol. 8, no. 4, Article ID e61834, 2013.
73. M. Munz, P. A. Baeuerle, and O. Gires, "The emerging role of EpCAM in cancer and stem cell signaling," Cancer Research, vol. 69, no. 14, pp. 5627-5629, 2009.
74. S. Mathivanan and R. J. Simpson, "ExoCarta: a compendium of exosomal proteins and RNA," Proteomics, vol. 9, no. 21, pp. 4997-5000, 2009.
75. L. H. K. Lim and S. Pervaiz, "Annexin 1: the new face of an old molecule," The FASEB Journal, vol. 21, no. 4, pp. 968-975, 2007.
76. Y. Tang, P. Kesavan, M. T. Nakada, and L. Yan, "Tumorstroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN," Molecular Cancer Research, vol. 2, no. 2, pp. 73-80, 2004.
77. C. Biswas and M. A. Nugent, "Membrane association of collagenase stimulatory factor(s) from B-16 melanoma cells," Journal of cellular biochemistry, vol. 35, no. 3, pp. 247-258, 1987.
78. K. Menck, F. Klemm, J. C. Gross, T. Pukrop, D. Wenzel, and C. Binder, "Induction and transport of Wnt 5a during macrophage-induced malignant invasion is mediated by two types of extracellular vesicles," Oncotarget, vol. 4, no. 11, pp. 2057-2066, 2013.
79. K. J. Radford, R. F. Torne, and P. Hersey, "Regulation of tumor cell motility and migration by CD63 in a human melanoma cell line," The Journal of Immunology, vol. 158, no. 7, pp. 3353-3358, 1997.
80. F. Berditchevski, G. Bazzoni, and M. E. Hemler, "Specifc association of CD63 with the VLA-3 and VLA-6 integrins," The Journal of Biological Chemistry, vol. 270, no. 30, pp. 17784-17790, 1995.
81. M. S. Kwon, S.-H. Shin, S.-H. Yim et al., "CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung," Lung Cancer, vol. 57, no. 1, pp. 46-53, 2007.
82. M. S. Pols and J. Klumperman, "Trafcking and function of the tetraspanin CD63," Experimental Cell Research, vol. 315, no. 9, pp. 1584-1592, 2009.
83. K.-K. Jung, X.-W. Liu, R. Chirco, R. Fridman, and H.-R. C. Kim, "Identifcation of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein," The EMBO Journal, vol. 25, no. 17, pp. 3934-3942, 2006.
84. R. Chirco, X.-W. Liu, K.-K. Jung, and H.-R. C. Kim, "Novel functions of TIMPs in cell signaling," Cancer and Metastasis Reviews, vol. 25, no. 1, pp. 99-113, 2006.
85. G. Odorizzi, "The multiple personalities of Alix," Journal of Cell Science, vol. 119, no. 15, pp. 3025-3032, 2006.
86. M. F. Baietti, Z. Zhang, E. Mortier et al., "Syndecan-syntenin-ALIX regulates the biogenesis of exosomes," Nature Cell Biology, vol. 14, no. 7, pp. 677-685, 2012.
87. C. Bissig and J. Gruenberg, "ALIX and the multivesicular endosome: ALIX in Wonderland," Trendsin Cell Biology, vol. 24, no. 1, pp. 19-25, 2014.
88. H. Larjava, T. Salo, K. Haapasalmi, R. H. Kramer, and J. Heino, "Expression of integrins and basement membrane components by wound keratinocytes," The Journal of Clinical Investigation, vol. 92, no. 3, pp. 1425-1435, 1993.
89. A. Melchiori, R. Mortarini, S. Carlone et al., "The β3β 1 integrin is involved in melanoma cell migration and invasion," Experimental Cell Research, vol. 219, no. 1, pp. 233-242, 1995.
90. C. Bouvard, Z. Segaoula, A. De Arcangelis et al., "Tie2-dependent deletion of β6 integrin subunit in mice reduces tumor growth and angiogenesis," International Journal of Oncology, vol. 45, no. 5, pp. 2058-2064, 2014.
91. R. Mukhopadhyay, R. L. Teriault, and J. E. Price, "Increased levels of β6 integrins are associated with the metastatic pheno-type of human breast cancer cells," Clinical and Experimental Metastasis, vol. 17, no. 4, pp. 325-332, 1999.
92. M. Morini, M. Mottolese, N. Ferrari et al., "The β3β1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity," International Journal of Cancer, vol. 87, no. 3, pp. 336-342, 2000.
93. K. Mitchell, K. B. Svenson, W. M. Longmate et al., "uppres-sion of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells," Cancer Research, vol. 70, no. 15, pp. 6359-6367, 2010.
94. S. P. Becerra and V. Notario, "The efects of PEDF on cancer biology: mechanisms of action and therapeutic potential," Nature Reviews Cancer, vol. 13, no. 4, pp. 258-271, 2013.
95. G. G. Sun, Y. F. Lu, Y. J. Cheng, and W. N. Hu, "The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis," Tumor Biology, vol. 35, no. 4, pp. 2949-2957, 2014.
96. J. Cai, C. Parr, G. Watkins, W. G. Jiang, and M. Boulton, "Decreased pigment epithelium-derived factor expression in human breast cancer progression," Clinical Cancer Research, vol. 12, no. 11, pp. 3510-3517, 2006.
97. D. J. Klinke, Y. M. Kulkarni, Y. Wu, and C. Byrne-Hofman, "Inferring alterations in cell-to-cell communication in HER2+ breast cancer using secretome profling of three cell models," Biotechnology and Bioengineering, vol. 111, no. 9, pp. 1853-1863, 2014.
98. L. Villarreal, O. Mendez, C. Salvans, J. Gregori, J. Baselga, and J. Villanueva, "Unconventional secretion is a major contributor of cancer cell line secretomes," Molecular and Cellular Proteomics, vol. 12, no. 5, pp. 1046-1060, 2013.
99. A. M. Sakwe, R. Koumangoye, B. Guillory, and J. Ochieng, "Annexin A6 contributes to the invasiveness of breast carcinoma cells by infuencing the organization and localization of functional focal adhesions," Experimental Cell Research, vol. 317, no. 6, pp. 823-837, 2011.
100. Y. Song, Q. Luo, H. Long et al., "Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma," Molecular Cancer, vol. 13, article 65, 2014.
101. W. Shi, K. Gerster, N. M. Alajez et al., "MicroRNA-301 mediates proliferation and invasion in human breast cancer," Cancer Research, vol. 71, no. 8, pp. 2926-2937, 2011.
102. H. Yu, H. Li, H. Qian et al., "Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer," Medical Oncology, vol. 31, article 283, 2014.
103. A. Suetsugu, K. Honma, S. Saji, H. Moriwaki, T. Ochiya, and R. M. Hofman, "Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models," Advanced Drug Delivery Reviews, vol. 65, no. 3, pp. 383-390, 2013.
104. W.-X. Chen, Y.-Q. Cai, M.-M. Lv et al., "Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs," Tumour Biology, vol. 35, no. 10, pp. 9649-9659, 2014.
105. C. Liu, S. Yu, K. Zinn et al., "Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function," The Journal of Immunology, vol. 176, no. 3, pp. 1375-1385, 2006.
106. A. Chow, W. Zhou, L. Liu et al., "Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-kappaB," Scientifc Reports, vol. 4, article 5750, 2014.
107. M. A. Antonyak, B. Li, L. K. Boroughs et al., "Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fbronectin to recipient cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 12, pp. 4852-4857, 2011.
108. C. S. Lau and D. T. W. Wong, "Breast cancer exosome-like microvesicles and salivary gland cells interplay alters salivary gland cell-derived exosome-like microvesicles in vitro," PLoS ONE, vol. 7, no. 3, Article ID e33037, 2012.
109. W. T. Bellamy, "P-glycoproteins and multidrug resistance," Annual Review of Pharmacology and Toxicology, vol. 36, pp. 161-183, 1996.
110. T. Yamagishi, S. Sahni, D. M. Sharp, A. Arvind, P. J. Jansson, and D. R. Richardson, "P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration," The Journal of Biological Chemistry, vol. 288, no. 44, pp. 31761-31771, 2013.
111. Y. Dong, Q. Pan, L. Jiang et al., "Tumor endothelial expression of P-glycoprotein upon microvesicular transfer of TrpC5 derived from adriamycin-resistant breast cancer cells," Biochemical and Biophysical Research Communications, vol. 446, no. 1, pp. 85-90, 2014.
112. M.-M. Lv, X.-Y. Zhu, W.-X. Chen et al., "Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein," Tu mor Biology, vol. 35, pp. 10773-10779, 2014.
113. Y. M. Li, Y. Pan, Y. Wei et al., "Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis," Cancer Cell, vol. 6, no. 5, pp. 459-469, 2004.
114. W. Dean-Colomb and F. J. Esteva, "Her2-positive breast cancer: herceptin and beyond," European Journal of Cancer, vol. 44, no. 18, pp. 2806-2812, 2008.
115. S. Huang, J. M. Trujillo, and S. Chakrabarty, "Proliferation of human colon cancer cells: role of epidermal growth factor and transforming growth factorβ," International Journal of Cancer, vol. 52, no. 6, pp. 978-986, 1992.
116. P. J. Russell, S. Bennett, and P. Stricker, "Growth factor involvement in progression of prostate cancer," Clinical Chemistry, vol. 44, no. 4, pp. 705-723, 1998.
117. C. Stove, T. Boterberg, V. Van Marck, M. Mareel, and M. Bracke, "Bowes melanoma cells secrete heregulin, which can promote aggregation and counteract invasion of human mammary cancer cells," International Journal of Cancer, vol. 114, no. 4, pp. 572-578, 2005.
118. J. L. Macdonald-Obermann, D. Piwnica-Worms, and L. J. Pike, "Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging," Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 1, pp. 137-142, 2012.
119. W. E. Holmes, M. X. Sliwkowski, R. W. Akita et al., "Identifca-tion of heregulin, a specifc activator of p185erbB2," Science, vol. 256, no. 5060, pp. 1205-1210, 1992.
120. C. Battke, R. Ruiss, U. Welsch et al., "Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC," Cancer Immunology, Immunotherapy, vol. 60, no. 5, pp. 639-648, 2011.
121. K. Shedden, X. T. Xie, P. Chandaroy, Y. T. Chang, and G. R. Rosania, "Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profles," Cancer Research, vol. 63, no. 15, pp. 4331-4337, 2003.
122. Y. Tian, S. Li, J. Song et al., "A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy," Biomaterials, vol. 35, no. 7, pp. 2383-2390, 2014.
123. N. C. Wong, B. M. Mueller, C. F. Barbas et al., "Alphav integrins mediate adhesion and migration of breast carcinoma cell lines," Clinical and Experimental Metastasis, vol. 16, pp. 50-61, 1998.
124. J.-Y. Jang, J.-K. Lee, Y.-K. Jeon, and C.-W. Kim, "Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infltration and M2 polarization," BMC Cancer, vol. 13, article 421, 2013.
125. A. Dey, J. Allen, and P. A. Hankey-Giblin, "Ontogeny and polarization of macrophages in infammation: blood monocytes versus tissue macrophages," Frontiers in Immunology, vol. 5, article 683, 2014.
126. A. Sica, T. Schioppa, A. Mantovani, and P. Allavena, "Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy," European Journal of Cancer, vol. 42, no. 6, pp. 717-727, 2006.
127. C.-Y. Liu, J.-Y. Xu, X.-Y. Shi et al., "M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway," Laboratory Investigation, vol. 93, no. 7, pp. 844-854, 2013.
128. M. T. Isla Larrain, M. E. Rabassa, E. Lacunza et al., "IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis," Tumor Biology, vol. 35, no. 7, pp. 6511-6519, 2014.
129. S. Yu, C. Liu, K. Su et al., "Tumor exosomes inhibit diferenti-ation of bone marrow dendritic cells," Journal of Immunology, vol. 178, no. 11, pp. 6867-6875, 2007.
130. E.-H. Hong, S.-Y. Chang, B.-R. Lee et al., "Blockade of Myd88 signaling induces antitumor efects by skewing the immunosup-pressive function of myeloid-derived suppressor cells," International Journal of Cancer, vol. 132, no. 12, pp. 2839-2848, 2013.
131. Y. Liu, X. Xiang, X. Zhuang et al., "Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells," American Journal of Pathology, vol. 176, no. 5, pp. 2490-2499, 2010.
132. X. Xiang, A. Poliakov, C. Liu et al., "Induction of myeloid-derived suppressor cells by tumor exosomes," International Journal of Cancer, vol. 124, no. 11, pp. 2621-2633, 2009.
133. H.-G. Zhang, H. Kim, C. Liu et al., "Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity," Biochimica et Biophysica Acta: Molecular Cell Research, vol. 1773, no. 7, pp. 1116-1123, 2007.
134. H. Das, V. Groh, C. Kuijl et al., "MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent efector function," Immunity, vol. 15, no. 1, pp. 83-93, 2001.
135. A. Steinle, P. Li, D. L. Morris et al., "Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family," Immunogenetics, vol. 53, no. 4, pp. 279-287, 2001.
136. + T cells," Blood, vol. 103, no. 8, pp. 3065-3072, 2004.
137. V. Groh, R. Rhinehart, J. Randolph-Habecker, M. S. Topp, S. R. Riddell, and T. Spies, "Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells," Nature Immunology, vol. 2, no. 3, pp. 255-260, 2001.
138. G. Chitadze, M. Lettau, J. Bhat et al., "Shedding of endogenous MHC class I-related chain molecules A and B from diferent human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17," International Journal of Cancer, vol. 133, no. 7, pp. 1557-1566, 2013.
139. Z. Deng, Z. Cheng, X. Xiang et al., "Tumor cell cross talk with tumor-associated leukocytes leads to induction of tumor exosomal fbronectin and promotes tumor progression," The American Journal of Pathology, vol. 180, no. 1, pp. 390-398, 2012.
140. J. Jarczak, E. M. Kósciuczuk, P. Lisowski et al., "Defensins: natural component of human innate immunity," Human Immunology, vol. 74, no. 9, pp. 1069-1079, 2013.
141. V. S. De Paula, N. S. F. Gomes, L. G. Lima et al., "Structural basis for the interaction of human beta-defensin 6 and its putative chemokine receptor CCR2 and breast cancer microvesicles," Journal of Molecular Biology, vol. 425, no. 22, pp. 4479-4495, 2013.
142. F. M. Vega and A. J. Ridley, "Rho GTPases in cancer cell biology," FEBS Letters, vol. 582, no. 14, pp. 2093-2101, 2008.
143. S. P. Fortin Ensign, I. T. Mathews, M. H. Symons, M. E. Berens, and N. L. Tran, "Implications of Rho GTPase signaling in glioma cell invasion and tumor progression," Frontiers in Oncology, vol. 3, article 241, 2013.
144. S. Schlienger, S. Campbell, and A. Claing, "ARF1 regulates the Rho/MLC pathway to control EGF-dependent breast cancer cell invasion," Molecular Biology of the Cell, vol. 25, no. 1, pp. 17-29, 2014.
145. D. L. Crowe and C. F. Shuler, "Regulation of tumor cell invasion by extracellular matrix," Histology and Histopathology, vol. 14, no. 2, pp. 665-671, 1999.
146. J. Westermarck and V.-M. Kähäri, "Regulation of matrix metal-loproteinase expression in tumor invasion," The FASEB Journal, vol. 13, no. 8, pp. 781-792, 1999.
147. L. G. Lima, A. C. Leal, G. Vargas, I. Porto-Carreiro, and R. Q. Monteiro, "Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles," Trombosis Research, vol. 132, no. 4, pp. 450-456, 2013.
148. A. M. Gil-Bernabe, S. Lucotti, and R. J. Muschel, "Coagulation and metastasis: what does the experimental literature tell us?" British Journal of Haematology, vol. 162, no. 4, pp. 433-441, 2013.
149. G. Bendas and L. Borsig, "Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins," International Journal of Cell Biology, vol. 2012, Article ID 676731, 10 pages, 2012.
150. M. Z. Wojtukiewicz, D. G. Tang, K. K. Nelson, D. A. Walz, C. A. Diglio, and K. V. Honn, "Trombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface," Trombosis Research, vol. 68, no. 3, pp. 233-245, 1992.
151. O. Galindo-Hernandez, C. Gonzales-Vazquez, P. Cortes-Reynosa et al., "Extracellular vesicles from women with breast cancer promote an epithelial-mesenchymal transition-like process in mammary epithelial cells MCF10A," Tumor Biology, pp. 1-11, 2015.
152. M. L. Alpaugh, J. S. Tomlinson, Z.-M. Shao, and S. H. Barsky, "A novel human xenograf model of infammatory breast cancer," Cancer Research, vol. 59, no. 20, pp. 5079-5084, 1999.
153. N. Dhani, A. Fyles, D. Hedley, and M. Milosevic, "The clinical signifcance of hypoxia in human cancers," Seminars in Nuclear Medicine, vol. 45, no. 2, pp. 110-121, 2015.
154. Y. Kato, S. Ozawa, C. Miyamoto et al., "Acidic extracellular microenvironment and cancer," Cancer Cell International, vol. 13, article 89, 2013.
155. C. Federici, F. Petrucci, S. Caimi et al., "Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin," PLoS ONE, vol. 9, no. 2, Article ID e88193, 2014.
156. B. Y. Wang, J. Zhang, J. L. Wang et al., "Intermittent high dose proton pump inhibitor enhances the antitumor efects of chemotherapy in metastatic breast cancer," Journal of Experimental & Clinical Cancer Research, vol. 34, no. 1, article 85, 2015.
157. A. Papi, S. De Carolis, S. Bertoni et al., "PPARgamma and RXR ligands disrupt the infammatory cross-talk in the hypoxic breast cancer stem cells niche," Journal of Cellular Physiology, vol. 229, no. 11, pp. 1595-1606, 2014.
158. Z. J. Yang, C. E. Chee, S. Huang, and F. A. Sinicrope, "The role of autophagy in cancer: therapeutic implications," Molecular Cancer Terapeutics, vol. 10, no. 9, pp. 1533-1541, 2011.
159. D. Glick, S. Barth, and K. F. Macleod, "Autophagy: cellular and molecular mechanisms," Journal of Pathology, vol. 221, no. 1, pp. 3-12, 2010.
160. J. A. Cho, H. Park, E. H. Lim, and K. W. Lee, "Exosomes from breast cancer cells can convert adipose tissue-derived mes-enchymal stem cells into myofbroblast-like cells," International Journal of Oncology, vol. 40, no. 1, pp. 130-138, 2012.
161. A. Desmoulìere, C. Guyot, and G. Gabbiani, "The stroma reaction myofbroblast: a key player in the control of tumor cell behavior," International Journal of Developmental Biology, vol. 48, no. 5-6, pp. 509-517, 2004.
162. W. Zhou, M. Y. Fong, Y. Min et al., "Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis," Cancer Cell, vol. 25, no. 4, pp. 501-515, 2014.
163. P. Sekar, J. N. Bharti, J. S. Nigam, A. Sharma, and P. B. Soni, "Evaluation of p53, HoxD10, and E-cadherin status in breast cancer and correlation with histological grade and other prognostic factors," Journal of Oncology, vol. 2014, Article ID 702527, 4 pages, 2014.
164. H. Lu, W. Ouyang, and C. Huang, "Infammation, a key event in cancer development," Molecular Cancer Research, vol. 4, no. 4, pp. 221-233, 2006.
165. T. M. Robinson-Smith, I. Isaacsohn, C. A. Mercer et al., "Macrophages mediate infammation-enhanced metastasis of ovarian tumors in mice," Cancer Research, vol. 67, no. 12, pp. 5708-5716, 2007.